Lisata Therapeutics, Inc. and Qilu Pharmaceutical Co. Ltd. announced that the first patient has been treated in Qilu?s Phase 2 trial in China evaluating LSTA1 , Lisata?s lead product candidate, in.
/PRNewswire/ The "Biosimilar Monoclonal Antibodies Global Market Report 2024" has been added to ResearchAndMarkets.com s offering. The expansion of the.
/PRNewswire/ On January 29th, the results of the phase II study on Qilu Pharmaceutical s novel anticancer drug iparomlimab and tuvonralimab (QL1706) were.
/PRNewswire/ The interim analysis results from the phase III INSPIRE study of iruplinalkib developed by Qilu Pharmaceutical, which focuses on the first-line.
/PRNewswire/ During the ESMO Immuno-Oncology Congress 2023 held in Geneva, Switzerland, from December 6th to 8th, Qilu Pharmaceutical presented the latest.